Jean-Charles Soria

By March 29, 2019

Jean-Charles Soria joined Medimmune Sept 13, 2017 as Senior Vice President of R&D and Head of Oncology iMED. Dr Soria has overall responsibility for the global oncology portfolio at Medimmune with oversight of research, translational sciences and clinical development in oncology.

Previously, he was a Professor of Medicine and Medical Oncology at South-Paris University from 2006-2017, and a tenure-track and full-time cancer specialist at Institut Gustave Roussy. Dr Soria trained as a medical oncologist and obtained the Silver medal from Paris Medical School in 1997. He gained a PhD degree in the fundamental basis of oncogenesis in 2001, and completed his training with a two-year post-doctoral fellowship in the Department of Thoracic Head and Neck Medical Oncology at MD Anderson Cancer Center, Houston, USA, where he has held an Adjunct Professorship in 2012.

During his career, Dr Soria’s main research interests have been: early clinical development, phase I trials across solid tumors, pharmacodynamic biomarkers, lung cancer and personalized medicine. He was also involved in translational research aspects related to precision medicine and tumor progression notably in lung cancer models (INSERM unit 981). Dr Soria has led multiple precision medicine trials including the MOSCATO trial and the French national effort SAFIR02lung trial. Dr Soria was a member of ESMO Executive Committee from 2008 to 2009, and has served as an ASCO committee member from 2006 to 2012. He was the scientific chairman of the ECCO-ESMO 2011 meeting that was held in Stockholm in 2011, and chair of the EORTC-NCI-AACR meeting in Barcelona in 2014, as well as in Berlin in 2016. He was the President of the TAT meeting in 2013, 2015 and 2017 in Paris. He has contributed to over 560 peer-reviewed publications, including publications as first or last author in the New England Journal of Medicine, the Journal of the National Cancer Institute, and the Journal of Clinical Oncology. He was appointed as Editor in Chief of Annals of Oncology for the period 2014-2017.


Join our Mailing List